Chiropractors in Metropolis, IL Accepting Medicare

8 Chiropractors found. Showing 1 - 8

Chiropractic Works Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 723 Market St, Metropolis, IL 62960 Phone: 618-524-8300    Fax: 618-524-8607

Dr. Fred White, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 209 W 10th St, Metropolis, IL 62960 Phone: 618-524-2001

Jeffrey Don Lange Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 810 Market St, Metropolis, IL 62960 Phone: 618-524-7575    Fax: 618-524-7262

Glass Chiropractic And Wellness Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 810 Market St, Metropolis, IL 62960 Phone: 618-524-5151

Dr. Leila Christina Lindquist, D.C. Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 723 Market St, Metropolis, IL 62960 Phone: 618-524-8300    Fax: 618-524-8607

Dr. Jacob Richard Glass, D. C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 810 Market St, Metropolis, IL 62960 Phone: 618-524-5151

Jeffrey Lange, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 810 Market St, Metropolis, IL 62960 Phone: 618-524-7575

Dr. Ronald Dale Teddleton, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 723 Market St, Metropolis, IL 62960 Phone: 618-638-5954    Fax: 618-524-8607

News Archive

ANCI signs agreement with Annapolis for healthcare solution

American CareSource Holdings, Inc., the nation's leading ancillary health care network services company, announced today that it has signed and implemented an agreement with Annapolis, Maryland-based Self Funding Administrators Corporation, a third party administrator representing an additional 30,000 covered lives.

TIR-199 shows promise in fighting renal cancer

Chemists at the University of California, Riverside have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer.

POZEN presents data from PA32540 Phase 1 gastric acid reduction study at DDW 2012

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from a Phase 1 study that found that the investigational compound, PA32540, provides faster protection compared with delayed-release, enteric-coated omeprazole (40 mg), as measured by mean time to gastric pH.

Study examines impact of tobacco smoke carcinogen on mice

Although tobacco use is widely understood to be one of the leading causes of oral cancer, research on the prevention of tobacco-related oral cancer in experimental animals has traditionally been limited to examining the impact of synthetic carcinogens manufactured especially for cancer research, rather than on observing the effects of carcinogens that occur in tobacco smoke.

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that activity and tolerance data for its second lead product Col-Treg were presented through a poster presentation at the 2015 ARVO Annual Meeting, May 3-7, 2015, in Denver, Colorado, US.

Read more Medical News

› Verified 4 days ago